Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Roopa Srikantiah-Saha

Medical Oncology Lancaster, OH Medical Doctor

NPI 1396856191 CMS profile 335487

135 N Ewing St, Suite 304, Lancaster, OH 43130

Open in the dashboard

General payments

$14,123

400 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Roopa Srikantiah-Saha of Lancaster, OH is reported in the CMS Open Payments database as having received $14,123 across 400 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Medical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,869 104
2024 General $2,785 103
2023 General $1,219 58
2022 General $1,515 47
2021 General $842 42
2020 General $1,568 32
2019 General $326 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Roopa Srikantiah-Saha
  • Medical Oncology median
  • Middle half of Medical Oncology
  • National median

In program year 2025, general payments to Roopa Srikantiah-Saha were reported at $5,869. Among 3,316 Medical Oncology profiles paid that year, the median was $1,128 and the middle half received between $147 and $5,675.

Show as a table
Year Roopa Srikantiah-Saha Medical Oncology median Middle half National median
2019 $326 $968 $140–$6,658 $163
2020 $1,568 $747 $102–$5,891 $114
2021 $842 $430 $50–$4,098 $132
2022 $1,515 $812 $127–$4,907 $149
2023 $1,219 $957 $144–$5,248 $160
2024 $2,785 $1,042 $149–$5,650 $164
2025 $5,869 $1,128 $147–$5,675 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $2,539 27 payments
  2. Janssen Biotech, Inc. $2,094 21 payments
  3. Pfizer Inc. $965 23 payments
  4. Incyte Corporation $781 29 payments
  5. GlaxoSmithKline, LLC. $635 7 payments
  6. Merck Sharp & Dohme Corporation $621 30 payments
  7. Genentech USA, Inc. $426 24 payments
  8. Astellas Pharma US Inc $420 9 payments
  9. Daiichi Sankyo Inc. $419 15 payments
  10. Athenex Pharmaceutical Division, LLC $325 2 payments
  11. Other $4,899 213 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,029 360 payments
  2. Consulting Fee $4,843 7 payments
  3. Education $1,513 27 payments
  4. Honoraria $575 3 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $135 2 payments
  6. Travel and Lodging $29 1 payment
Products named General payments · program years 2019–2025
  1. RYBREVANT $1,804 8 payments
  2. KEYTRUDA $621 30 payments
  3. DAURISMO $600 1 payment
  4. BLENREP $442 2 payments
  5. ENHERTU $393 14 payments
  6. MONJUVI $390 16 payments
  7. FOTIVDA $291 11 payments
  8. BRAFTOVI $264 16 payments
  9. MEKTOVI $250 15 payments
  10. myRisk $238 2 payments
  11. Other $8,093 411 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

803

Median for Hematology-Oncology: 604

Drug cost

$3,341,114

Median for Hematology-Oncology: $1,306,514

Branded share of claims

36.9%

Median for Hematology-Oncology: 31.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Revlimid Lenalidomide Brand 49 $735,968
Calquence Acalabrutinib Maleate Brand 45 $698,426
Kisqali Ribociclib Succinate Brand 27 $469,205
Lenalidomide Generic 33 $362,611
Inlyta Axitinib Brand 13 $224,995
Ibrance Palbociclib Brand 12 $193,704
Imbruvica Ibrutinib Brand 12 $184,812
Abiraterone Acetate Generic 35 $177,438
Nubeqa Darolutamide Brand 12 $167,068
Verzenio Abemaciclib Brand 13 $99,495

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$70,093

Medicare's payments for the services billed

Medicare patients

245

Average age 75

Services billed

631

124 women, 121 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 53%
Ischemic heart disease 43%
Arthritis 42%
Diabetes 38%
COPD 38%
Chronic kidney disease 36%
Atrial fibrillation 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 58 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENHERTU
  • Daiichi Sankyo Inc. $255
  • AstraZeneca Pharmaceuticals LP $15
$270 — —
KEYTRUDA
  • Merck Sharp & Dohme Corporation $196
$196 — —
Vyloy
  • Astellas Pharma US Inc $125
$125 — —
FOTIVDA
  • Aveo Pharmaceuticals, Inc. $124
$124 — —
Padcev
  • Astellas Pharma US Inc $66
  • PFIZER INC. $36
$102 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 58 with Patron

Records

400 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record